Lataa...
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
Current non-small cell lung cancer (NSCLC) chemotherapy and radiotherapy regimens, although showing definite survival benefit, still leave patients with a disappointing 15% 5-year overall survival rate. Because of the need to improve traditional outcomes, research has focused on identifying specific...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2990321/ https://ncbi.nlm.nih.gov/pubmed/21116327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S8617 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|